TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.

Phyo Pyae Nyein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.